# Perspective Therapeutics (CATX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CATX
## Company Profile
- Ticker: CATX
- Exchange: AMEX
- Sector: Biopharma
- Location: United States
- Tags: Radiopharmaceuticals, Oncology
## Stock Data
- Close: 3.26 USD
- Market cap: 410566309.2 USD
- Last updated: 2026-08-12
## Business Overview
### Lead-212 Radiopharmaceuticals
Perspective Therapeutics develops targeted radiopharmaceuticals using the alpha-emitting isotope lead-212. Specialized targeting molecules carry radiation to cancer cells, while related imaging agents can support patient selection and dosimetry.
### VMT-Alpha-NET
VMT-α-NET is a lead-212 radiopharmaceutical in Phase 1/2a development for neuroendocrine tumors. Clinical results have shown durable disease control and deepening responses with longer follow-up, supporting further dose and patient-selection analysis.
### VMT01
VMT01 targets the melanocortin-1 receptor in melanoma. It can be labeled with lead-203 for imaging and dosimetry or lead-212 for alpha-particle therapy, creating a matched diagnostic and therapeutic approach.
### PSV359
PSV359 is another lead-212 program in Phase 1/2a development for solid tumors. It broadens Perspective’s clinical evaluation beyond neuroendocrine tumors and melanoma.
### Distributed Manufacturing
Perspective is building regional finishing facilities supported by proprietary lead-212 generators. This network is intended to deliver short-lived radiopharmaceutical doses to clinical sites and eventually support commercial supply.
## Why The Stock Is Moving

As of Aug 12, 2026, CATX closed up 2.52% at $3.26. No new same-company headline was identified in the current news window.

## Future Catalysts

- Approximately one year of follow-up for all 46 VMT-α-NET Cohort 2 patients expected by mid-2026.
- Clinical updates from VMT-α-NET, VMT01 and PSV359 planned for submission to medical conferences during 2026.
- At least 24 weeks of follow-up for recently treated VMT01 patients expected by late 2026.

## Recent News
- 2026-08-10 20:22 EST — [Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results](https://biopharmsignal.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2026-4479e0c1) — Source: Perspective Therapeutics
- 2026-07-31 10:30 EST — [Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/CATX/perspective-therapeutics-to-provide-business-highlights-and-report-second-quarte-9488302c) — Source: Perspective Therapeutics
- 2026-07-28 10:30 EST — [Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs](https://biopharmsignal.com/news/CATX/perspective-therapeutics-receives-european-orphan-medicinal-product-designation--6620bea5) — Source: Perspective Therapeutics
- 2026-07-17 16:22 EST — [Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026](https://biopharmsignal.com/news/CATX/perspective-therapeutics-announces-acceptance-of-vmt-net-data-for-oral-presentat-0e2c17aa) — Source: Perspective Therapeutics
- 2026-07-08 10:30 EST — [Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor](https://biopharmsignal.com/news/CATX/perspective-therapeutics-appoints-paul-lyne-ph-d-as-chief-science-officer-co-fou-463c2453) — Source: Perspective Therapeutics